Russell Investments Group
ZNTL icon

Russell Investments Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Russell Investments Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4K Buy
+4,000
New +$16K ﹤0.01% 3812
2025
Q3 		– Sell
-150,990
Closed -$175K – 4237
2025
Q2 		$175K Sell
150,990
-1,265
-0.8% -$1.67K ﹤0.01% 2684
2025
Q1 		$242K Buy
152,255
+92,234
+154% +$199K ﹤0.01% 2535
2024
Q4 		$182K Buy
60,021
+37,726
+169% +$124K ﹤0.01% 2562
2024
Q3 		$82K Buy
+22,295
New +$81K ﹤0.01% 2696
2023
Q4 		– Sell
-99,412
Closed -$1.99M – 3319
2023
Q3 		$1.99M Sell
99,412
-6,461
-6% -$164K ﹤0.01% 1545
2023
Q2 		$2.99M Buy
105,873
+50,803
+92% +$1.22M 0.01% 1331
2023
Q1 		$947K Sell
55,070
-18,281
-25% -$370K ﹤0.01% 1996
2022
Q4 		$1.48M Sell
73,351
-6,415
-8% -$138K ﹤0.01% 1769
2022
Q3 		$1.73M Buy
79,766
+1,978
+3% +$54.1K ﹤0.01% 1634
2022
Q2 		$2.18M Buy
77,788
+19,169
+33% +$508K ﹤0.01% 1541
2022
Q1 		$2.7M Sell
58,619
-645
-1% -$34.8K ﹤0.01% 1478
2021
Q4 		$4.98M Buy
59,264
+1,751
+3% +$135K 0.01% 1252
2021
Q3 		$3.83M Buy
57,513
+10,990
+24% +$634K 0.01% 1410
2021
Q2 		$2.47M Buy
46,523
+23,187
+99% +$1.24M ﹤0.01% 1781
2021
Q1 		$1.01M Hold
23,336
– – ﹤0.01% 2240
2020
Q4 		$1.21M Buy
+23,336
New +$1.05M ﹤0.01% 2037

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Russell Investments Group's ZNTL Position: Q2 2026 in Review

Russell Investments Group opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 4,000 shares worth $19.4K. The stake represents ﹤0.01% of the portfolio and ranks #3812 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in ZNTL as recently as Q2 2025.

Russell Investments Group first reported a position in ZNTL in Q4 2020 and has held it in 17 quarters since. The position peaked at $4.98M in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Russell Investments Group held 4,000 shares of Zentalis Pharmaceuticals worth $19.4K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Russell Investments Group position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3812 holding.
  • Russell Investments Group first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 17 quarters since.
  • Russell Investments Group's Zentalis Pharmaceuticals position peaked at $4.98M in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.